All In Biotech

Drug Trial Radar · NCT04694248

Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting

Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

172

Planned (sponsor's estimate)

Start

Nov 3, 2021

Primary completion

Dec 31, 2026

Study completion Jun 30, 2027

Sponsor

Lead sponsor
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ningbo No.2 Hospital; Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University; The Central Hospital of Lishui City; Taizhou Enze Medical Center Group; Taizhou First People's Hospital; Boston Scientific Corporation
First posted
Jan 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of combination of anticoagulant and antiplatelet therapy on the patency of iliac vein at 12-month post stenting in patients with acute proximal DVT and ipsilateral iliac vein stenosis who received percutaneous mechanic thrombectomy and iliac vein stenting.

Conditions

  • Deep Vein Thrombosis
  • Iliac Vein Thrombosis
  • Iliac Vein Obstruction
  • Iliac Vein Stenosis
  • Iliac Vein Compression Syndrome

Interventions

  • RivaroxabanDrug

    For anticoagulant, it is rivaroxaban 20mg once a day for 6 months.

  • AspirinDrug

    For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Effectiveness EndpointsTime frame: 12-month follow-up
  2. Primary Safety EndpointsTime frame: 12-month follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affliated Hospital, Zhejiang University, School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.